510(k) Report

510(k) · Cleared

Cleared

Amylase2

K210633510(k) TraditionalCleared May 26, 2022449-day reviewClass II21 CFR 862.1070

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Abbott Ireland Diagnostics Division · JFJ Catalytic Methods, Amylase

Cleared on May 26, 2022 as substantially equivalent to K981653 (Abbott Laboratories, 1998) after a 449-day review. Its family tree reaches back 2 generations to 1989.

Decided
May 26, 2022
Review
449 days
Class
Class II
Product code
JFJ
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K882225 (1989). No later device cites it as a predicate yet.

  1. Root · 2 generations backK882225 -Amylase EpsBoehringer Mannheim Corp. · 1989
  2. 1 generation backK981653 AMYAbbott Laboratories · 1998
  3. This deviceK210633 Amylase2Abbott Ireland Diagnostics Division · 2022
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K882225-Amylase EpsBoehringer Mannheim Corp.1989—
−1K981653AMYAbbott Laboratories1998—
0 (this device)K210633Amylase2Abbott Ireland Diagnostics Division2022—
FIG. 1 — Lineage of K210633, 1989–2022Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in JFJ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K981653AMY
Summary page 5
…ssification: Class II Classification Name: Amylase test system Governing Regulation Number: 21 CFR 862.1070 Product Code: JFJ IV. Predicate Device AMY (k981653) V. Description of Device Principles of the Procedure The Amylase2 assay is an automated clinical chemistry assa…
Abbott Laboratories1998—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 33 years and passes through 3 companies; a new generation was cleared every 23.7 years on median.
  • None of the 2 ancestors has a recall.

How does its category compare?

All JFJ devices

JFJ Catalytic Methods, Amylase: FDA decisions, review times, recalls and adverse event reports over 20 years. 2022, this device’s year, is highlighted.

FDA decisions per year · JFJ

1in 2022

2007: 12008: 12009: 12012: 12013: 12019: 22022: 1
2007high 2 (2019) · low 0 (2010)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · JFJ

Too few JFJ 510(k)s in any year since 2007 to give a median.

Recalls per year · JFJ

1in 2007

2007: 1
2007high 1 (2007) · low 0 (2008)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · JFJ

1in 2025

2010: 12011: 22012: 12018: 22020: 12022: 12024: 12025: 1
2007high 2 (2011) · low 0 (2007)2025

MAUDE reports naming product code JFJ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—10
20081—00
20091—00
20100—01
20110—02
20121—01
20131—00
20140—00
20150—00
20160—00
20170—00
20180—02
20192—00
20200—01
20210—00
20221—01
20230—00
20240—01
20250—01
20260—0—

What is it indicated for?

The Amylase2 assay is used for the quantitation of amylase in human serum, plasma, or urine on the ARCHITECT c System. The Amylase2 assay is to be used primarily as an aid in the diagnosis and treatment of pancreatitis (inflammation of the pancreas).

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K210633: Amylase2.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K210633

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026